EUCTR2005-003459-12-SE进行中（未招募）不适用
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to compare the Efficacy and Safety of 60 mg/kg body weight of Zemaira® weekly i.v. administration with Placebo weekly i.v. administration in Chronic Augmentation and Maintenance Therapy in Subjects with Emphysema due to Alpha1-Proteinase Inhibitor Deficiency - N/A
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. 18 to 65 years of age and willing to sign informed consent.
- •2. Males, and non-pregnant, non-lactating females, whose screening pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator.
- •3. Diagnosis of alpha1-proteinase inhibitor deficiency (serum A1- PI levels <11 mM or < 80 mg/dL). This includes newly diagnosed subjects, previously untreated subjects, currently treated subjects, and subjects currently not on treatment therapy but on treatment in the past.
- •4. Subjects with emphysema and FEV1 > 35 and < 70% (predicted).
- •5. No signs of chronic or acute Hepatitis A, Hepatitis B, Hepatitis C or HIV infection (negative serologies for HIV and viral hepatitis). In case of positive serologies for viral hepatitis, vaccination status or negative IgM should be available.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 175
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1. Any relevant chronic diseases or history of relevant diseases (e.g., severe renal insufficiency) except respiratory or liver disease secondary to alpha1-proteinase inhibitor deficiency. Subjects with well-controlled, chronic diseases may be included
- •after consultation with the treating physician and the sponsor.
- •2. Current evidence of alcohol abuse or history of abuse of illegal and/or legally prescribed drugs such as barbiturates, benzodiazepines, amphetamines, cocaine, opioids, and cannabinoids.
- •3. History of allergy, anaphylactic reaction, or severe systemic response to human plasma derived products, or known mannitol hypersensitivity, or history of prior adverse reaction to mannitol.
- •4. History of transfusion reactions.
- •5. Selective IgA deficiency.
- •6. Acute illness within one week prior to the first administration of the investigational medicinal product (IMP). Start of treatment after recovery is possible.
- •7. Current tobacco smoker (smoking has to be ceased at least 6 months prior study inclusion). Subjects with a positive cotinine test due to nicotine replacement therapy (e.g. patches, chewing gum) or snuff are eligible.
- •8. Conditions or behaviors that interfere with attending scheduled study visits in opinion of the investigator.
- •9. History of non-compliance.
- •10. Administration of any other experimental new drug or participation in an investigation of a marketed product within one month prior to the screening visit date.
- •11. Inability to perform necessary study procedures.
- •12. Lung transplantation, lung volume reduction surgery or lobectomy or being on a waiting list for any such surgeries.
研究者
相似试验
进行中（未招募）
1 期
Clinical research study to measure how good and how safe Branebrutinib compared to a placebo is in treating participants with Systemic Lupus Erythematosus or Primary Sjögren’s Syndrome, or participants with Rheumatoid Arthritis when being treated with Branebrutinib and methotrexate followed with Abatacept treatment.SLE Sub-protocol: Systemic Lupus ErythematosuspSS Sub-protocol: Primary Sjögren’s SyndromeRA Sub-protocol: Rheumatoid ArthritisMedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 21.0Level: PTClassification code 10040767Term: Sjogren's syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 21.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2019-002205-22-ESBristol-Myers Squibb International Corporation185
进行中（未招募）
不适用
Clinical research study to evaluate safety and efficacy of alpha1-proteinase inhibitor (A1-PI) compared to placebo (a product that does not contain the active ingredient) administered intravenously to patients with deficiency of alpha1-proteinase inhibitor and emphysemaChronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.MedDRA version: 15.0Level: LLTClassification code 10001811Term: Alpha-1 proteinase inhibitor deficiencySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2005-003459-12-DKCSL Behring GmbH180
进行中（未招募）
1 期
A randomized, Placebo-Controlled, multicenter study to Evaluate Efficacy and Safety of Orally administered BT-11 in patients with Moderate to Severe Crohn’s Disease.Patients with Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2019-000824-17-ATandos Biopharma Inc.150
进行中（未招募）
1 期
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacyand Safety of Oral BT-11 in Mild to Moderate Ulcerative ColitisMild to Moderate Ulcerative Colitis Inflammatory bowel disease (IBD) is an autoimmune disease of the gastrointestinal (GI) tract with unknown etiology that encompasses 2 primary clinical manifestations: ulcerative colitis (UC) and Crohn’s disease (CD). UC manifests through complex interactions between the gut microbiome, dysregulated immune responses, genetic mutations, diet, and other environmental factors.MedDRA version: 20.0Level: PTClassification code 10009900Term: Colitis ulcerativeSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2018-005086-39-HUandos Biopharma Inc.195
进行中（未招募）
1 期
Clinical research study to evaluate safety and efficacy of alpha1-proteinase inhibitor (A1-PI) compared to placebo (a product that does not contain the active ingredient) administered intravenously to patients with deficiency of alpha1-proteinase inhibitor and emphysemaChronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.MedDRA version: 15.0Level: LLTClassification code 10001811Term: Alpha-1 proteinase inhibitor deficiencySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2005-003459-12-FICSL Behring GmbH180